Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CPT1A | P50416 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATP4A | P20648 | 1/20 | 0.38 |
| ▸ | ATP4B | P51164 | 1/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839905 | 0.94 | PPARG (0.51) | PPARGAPPLMNAADORA3MAPT | |
| SCHEMBL3840190 | 0.89 | PPARG (0.46) | PPARGLMNAADORA3KCNQ1MAPT | |
| SCHEMBL3840202 | 0.87 | PPARG (0.44) | PPARGCPT1AKCNQ1 | |
| SCHEMBL5376568 | 0.83 | ALOX5 (0.41) | PPARGAPPLMNACPT1AADORA3 | |
| SCHEMBL5376571 | 0.81 | APP (0.40) | PPARGAPPLMNACPT1ANPC1 | |
| SCHEMBL13588500 | 0.81 | PPARG (0.43) | PPARGNPC1RAB9AATP4AATP4B | |
| SCHEMBL3260605 | 0.80 | PPARG (0.54) | PPARG | |
| SCHEMBL1596544 | 0.80 | PPARG (0.54) | PPARG | |
| SCHEMBL5383278 | 0.76 | ELANE (0.53) | APPADORA3NPC1RAB9AMAPT | |
| SCHEMBL5379053 | 0.76 | LMNA (0.39) | LMNANPC1RAB9AATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160868-A1 | 3-Phenylpropionic acid derivatives | ADAMED, SP. Z.O.O. (PL) | 2006-07-20 | — | — | US | claimed |
| US-7309791-B2 | 3-phenylpropionic acid derivatives | ADAMED SP. Z.O.O (PL) | 2007-12-18 | — | — | US | disclosed |
| US-20060160868-A1 | 3-Phenylpropionic acid derivatives | ADAMED, SP. Z.O.O. (PL) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160868-A1 | 3-Phenylpropionic acid derivatives | PPARA, PPARG, PPARD | PPARG 2/4885APP 2415/4885LMNA 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.